Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew Xiuxuan Zhu, Richard S. Finn, Julien Edeline et al. · The Lancet Oncology · 2018
Cited by 2,474 works. doi:10.1016/s1470-2045(18)30351-6
Authors
- Andrew Xiuxuan Zhu
- Richard S. Finn
- Julien Edeline
- Stéphane Cattan
- Sadahisa Ogasawara
- Daniel H. Palmer
- Chris Verslype
- Vittorina Zagonel
- Lætitia Fartoux
- Arndt Vogel
- Debashis Sarker
- Gontran Verset
- Stephen Lam Chan
- Jennifer Jane Knox
- Bruno Daniele
- Andrea L. Webber
- Scot Ebbinghaus
- Junshui Ma
- Abby B. Siegel
- Ann‐Lii Cheng
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
- Sorafenib in Advanced Hepatocellular Carcinoma
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- Sorafenib in Advanced Hepatocellular Carcinoma
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial